The Ketamine Research Foundation (KRF)is proud to present its research on the presence/absence of ketamine in breast milk. As a first line antidepressant, ketamine in assisted psychotherapy (KAP) for women who are breast-feeding and suffering with postpartum depression (PPD), and depression and PTSD offers the option for intermittent use. This solves the dilemma for women seeking effective treatment and who do not wish to expose infants to continuous exposure to conventional treatments such as antidepressants. As the effects of long term continuous use of medication on infant development is unknown and difficult to study prospectively, the assurance of our study opens the door to a different and effective approach.
KRF is in the process of developing its protocol for PPD and we expect to launch in the Fall.
Contributions to our 501c3 Ketamine Research Foundation are deeply appreciated: ketamineresearchfoundation.org
KRF In Vanity Fair – Stolen Words: Covid, Ketamine, And Me
The Ketamine Research Foundation is proud to announce full FDA and IRB approval for Conscious Dying/Conscious Living, our protocol providing Ketamine Assisted Psychotherapy for those facing death with conscious intent. READ MORE.
Read the New Yorker Article that mentions our work here: Ketamine Therapy Is Going Mainstream. Are We Ready?
Dedicated
to research education and training
Introducing our latest project, the Indra’s Net Coalition. Please enjoy our brief summary video.
Training
Training the next generation of Ketamine practitioners
Research
Helping to understand the practical applications of Ketamine
Library
All studies from the beginning of research to current literature
Access
First of its kind funded Ketamine therapy for qualified patients
Our
Mission
Ketamine is the only legally available medicine with psychedelic properties, the first in the toolbox. This enables the development of therapeutic methodologies and practices that will serve as other medicines become available. It makes for streamlined and creative research —with appropriate safeguards and IRB approvals. The spectrum of programs and projects that are part of the developing Ketamine Research Foundation exemplifies this and our dedication to collaboration, an international organizational presence, and the fulfillment of ketamine’s promise as an extraordinary agent of change and growth.
Indra’s Net Coalition
Latest News
Utopian Proposal for the Psychedelic Community
Utopian Proposal for the Psychedelic Community...
Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy
Read the full article here:...
MAPS Phase 2 Study Published
KRF is Pleased to Announce the Publication of...
Training
The Ketamine Training Center (KTC) has sponsored twelve programs across the US and Canada, with almost 300 practitioners having participated in its four day plus follow-up programs. Training is both experiential and didactic in the essential spirit of ‘practitioners applying a psychedelic, psychoactive medicine to patients needing to know its powers and effects personally’. Our programs are continuing in 2020 with great enthusiasm for enrollment. We are in the process of program development in Europe and Latin America. Trainees have the option as they take up KAP practices of joining the Ketamine Psychotherapy Associates program to further develop and support KAP’s application worldwide.
Ketamine Psychotherapy Associates
KPA is a growing body of practitioners of KAP Internationally who adhere to our Mission and/or have been in a KTC training program. It serves as a consultative, referral, data collecting, developmental and advocacy body for KAP. Our goal is to become recognized as the go-to center for obtaining KAP psychotherapy from vetted practitioners. KPA is a membership organization under our non-profit structure.
The KRF Leadership Program
Our program is a Leadership Intensive. Having selected an initial group of 12 outstanding KAP practitioners with a wide variety of interests and skills, we are generating a collaborative collegial process of melding ourselves into a cohesive force for promoting training, education, and development of KAP methodology. Our goal is to expand our ability to bring KAP into widespread practice as an ethical, expansive, healing, and transformative psychotherapy.
KRF will be holding Advanced Training Programs, support for the development of KAP in academic settings, and an expansion of our Leadership group.
The Ketamine Data Project (KDP)
We provide a comprehensive view of our various ketamine practices on an independent site by site basis—demonstrating outcomes and efficacy—our study utilizes the Vanderbilt University Redcap system with the creation of assessment tools specific to KAP. We share HIPAA compliant data, and utilize a complex set of digital forms that can serve as the basic formats for patient data collection and longitudinal assessment. This has been demonstrated in our first ever KAP publication of this process with 235 patients from 3 separate sites, all unified by their participation in KDP, and their practitioners having participated in KTC training programs. We expect to publish much larger studies from a wider array of practices in the year ahead. KDP is accessed by membership in KPA as a benefit of belonging to it.
Research
As we are able to design and perform research within the legal status of ketamine—WHO worldwide–we are in the process of developing protocols to be funded and administered under KRF’s non=profit umbrella. We are welcoming new creative initiatives and are developing relations with collaborating researchers. Each project has its own cost center and donations to KRF may be earmarked. All studies will be IRB approved and registered.
Our list of active projects includes
End of Life
KAP for end of life/hospice patients—with its own unique measure for assessing goals, feelings and conflicts at the end of life, the ELI.
Anxiety/Depression
KAP for anxiety and depression related to life-threatening illnesses.
Addiction
KAP for opiate addiction to demonstrate ketamine’s effects on reduction in opiate use and recidivism utilizing KAP protocols adapted to addiction.
Postpartum
KAP for postpartum depression (PPD) will begin with the first ever measurement of ketamine in breast milk. We expect that mothers will be able to continue breast-feeding after a short respite given ketamine’s brief half life. We have just received IRB approval for the project and expect to finish in the beginning of 2020, moving then to a study of KAP for PPD. The Foundation has submitted a provisional patent for this use of ketamine which is novel. All potential financial benefits will accrue to KRF.
The Ketamine Library
The Ketamine Library is the flagship of the organization. Sharing the MAPS library format, it contains all human studies from the beginning of research on ketamine to current literature. It is regularly updated and serves as the core tool for ketamine research and education to the public at large and to practitioners and researchers.
Access to Care
Access to Care is the first of its kind program, providing support to those who cannot afford KAP. KRF gives limited funding on the basis of practitioner submission of eligibility for qualified patients to be able to receive KAP. It is only open for application to members of KPA. The economics of ketamine in the general ketamine practices are prohibitive for so many to obtain necessary care. KRF seeks funding to expand our ability to give this support.
